The Patent Trial and Appeal Board today released its 14th decision on a Coalition for Affordable Drugs inter partes review, denying a petition challenging a Celgene patent for the Pomalyst myeloma cancer treatment.
It is Celgene’s first good news in its disputes with hedge fund manager Kyle Bass at the PTAB, with trials instituted for four other IPRs challenging its patents. The Board had also rejected its motion to sanction Bass.
The decision also leaves Bass even in terms of institutions and denials so far, with seven petitions instituted (one of which was granted in part) and seven denied. The Coalition for Affordable Drugs, which was set up by Bass and Erich Spangenberg, has filed 33 petitions in total.
The Board should also give a decision this month on an IPR filed on May 21 challenging US Patent 6,926,907, which is owned by Pozen and covers the Vimovo treatment. Horizon Pharma bought the US rights to the stomach ulcer treatment in 2013.
In its latest institution decision, the PTAB said the information presented in the petition and accompanying evidence did not establish a reasonable likelihood that the Coalition for Affordable Drugs would prevail in showing the unpatentability of the challenged claims.
The institution decisions the PTAB has given on the Coalition's petitions so far are below.
For full details of all petitions filed by the Coalition as well as data on the most-active PTAB petitioners this year, subscribers and trialists can read our "Data: Analysing the busiest PTAB petitioners, patent owners and law firms so far in 2015" article here.
|INSTITUTION DECISIONS ON COALITION FOR AFFORDABLE DRUGS' IPRS |
|IPR number||Filed||Law firm used by the Coalition||Patent number||Patent owner||Drug used in||Instituted?|
|2015-00720||10 Feb||Skiermont Puckett||8,663,685||Acorda Therapeutics||Ampyra||NO|
|2015-00817||27 Feb||Skiermont Puckett||8,007,826||Acorda Therapeutics||Ampyra||NO|
|2015-00988||1 Apr||Skiermont Puckett||6,773,720||Cosmo/Nogra/Shire||Lialda||YES|
|2015-00990||1 Apr||Merchant & Gould||7,056,886||NPS/Shire||Gattex||YES|
|2015-01018||6 Apr||Merchant & Gould||7,895,059||Jazz Pharmaceuticals||Xyrem||NO|
|2015-01076||20 Apr||Merchant & Gould||8,754,090||Pharmacyclics||Imbruvica||NO|
|2015-01086||22 Apr||Neifeld IP Law||8,759,393||Biogen International||Tecfidera||NO|
|2015-01102||23 Apr||Skiermont Puckett||6,315,720||Celgene Corporation||Revlimid||YES|
|2015-01096||23 Apr||Skiermont Puckett||6,315,720||Celgene Corporation||Revlimid||YES|
|2015-01103||23 Apr||Skiermont Puckett||6,315,720||Celgene Corporation||Revlimid||YES|
|2015-01092||23 Apr||Skiermont Puckett||6,045,501||Celgene Corporation||Pomalyst, Revlimid, Thalomid||YES|
|2015-01093||23 Apr||Merchant & Gould||7,056,886||NPS/Shire||Gattex||YES (for some claims)|
|2015-01136||1 May||Neifeld IP Law||8,399,514||Biogen MA||Tecfidera||NO|
|2015-01169||7 May||Merchant & Gould||5,635,517||Celgene Corporation||Pomalyst||NO|
|The IPRs list the petitioners as the Coalition for Affordable Drugs, J Kyle Bass, Erich Spangenberg, Hayman Capital Management, various Hayman funds, IP Navigation Group, and nXn Partners|
|Source: Docket Navigator|
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2021 Euromoney Institutional Investor PLC. For help please see our FAQs.